6672.      Arya SC.An enzyme-linked immunosorbent assay (ELISA) format to diagnose Wuchereria bancrofti specific immunoglobulin G4 class in urine samples.Am J Trop Med Hyg  2002 Oct;67(4):335

6673.      Birley H, Duerden B, Hart CA, Curless E, Hay PE, Ison CA, Renton AM, Richens J, Wyatt GB.Sexually transmitted diseases: microbiology and management.J Med Microbiol  2002 Oct;51(10):793-807

6674.      Bregani ER, Ghiringhelli C, Ceraldi T, Rovellini A. Identification of Mansonella perstans microfilariae in ascitic fluid.Trop Doct  2002 Oct;32(4):249-50

6675.      Dash PK; Mishra GC; Pattanaik MR; Mohapatra N; Behera G. Clinical profile of tropical pulmonary eosinophilia with special reference to bronchoalveolar lavage  Antiseptic. 2002 Sep; 99(9): 332-4

6676.      Kipp W, Bamhuhiiga J. Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda. Am J Trop Med Hyg  2002 Nov;67(5):475-9

6677.      Kundu AK, Giri A, Ghosh G, Saha SR.Microfilaria in a thyroid nodule which resolved on treatment. Trop Doct  2002 Oct;32(4):248

6678.      R. Alli, B. Bhunia, GP Chhotray, MVR Reddy, BC Harinath. Microscopic haematuria as an occult filarial infection in Bhubaneshwar an endemic area for bancroftian filariasis. Indian J of Clin Biochem 2003, 18 (1): 61-64.

6679.      Stringfellow GJ, Francis IC, Coroneo MT, Walker J.Orbital dirofilariasis. Clin Experiment Ophthalmol  2002 Oct;30(5):378-80

6679.Supali T, Ismid IS, Ruckert P, Fischer P. Treatment of Brugia timori and Wuchereria bancrofti infections in Indonesia using DEC or a combination of DEC and albendazole: adverse reactions and short-term effects on microfilariae.Trop Med Int Health  2002 Oct;7(10):894-901

Pathogenesis:

6680.      Bockarie MJ, Tisch DJ, Kastens W, Alexander ND, Dimber Z, Bockarie F, Ibam E, Alpers MP, Kazura JW. Mass treatment to eliminate filariasis in Papua New Guinea.N Engl J Med  2002 Dec 5;347(23):1841-8

6681.      Cooper PJ, Schwartz LB, Irani AM, Awadzi K, Guderian RH, Nutman TB. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin. J Infect Dis  2002 Nov 1;186(9):1307-13

6682.      Doan NM, Keiser PB, Bates RA, Fedorko DP, Weina PJ, Lucey DR. A 33-year-old woman from Nigeria with eosinophilia. Clin Infect Dis  2002 Nov 15;35(10):1204, 1263-4

6683.      Duke BO, Marty AM, Peett DL, Gardo J, Pion SD, Kamgno J, Boussinesq M. Neoplastic change in Onchocerca volvulus and its relation to ivermectin treatment. Parasitology  2002 Nov;125(Pt 5):431-44

6684.      McCarroll L, Hemingway J.Can insecticide resistance status affect parasite transmission in mosquitoes? Insect Biochem Mol Biol  2002 Oct;32(10):1345-51

6685.      Roberts L.Mosquitoes and disease. Science  2002 Oct 4;298(5591):82-3

6686.      Shriram AN, Murhekar MV, Ramaiah KD, Sehgal SC. Prevalence of diurnally subperiodic bancroftian filariasis among the Nicobarese in Andaman and Nicobar Islands, India: effect of age and gender. Trop Med Int Health  2002 Nov;7(11):949-54

Therapy:

6687.      Onwujekwe O, Chima R, Shu E, Okonkwo P. Community-directed treatment with ivermectin in two Nigerian communities: an analysis of first year start-up processes, costs and consequences. Health Policy  2002 Oct;62(1):31-51

6688.      Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med  2002 Dec 5;347(23):1885-6 

6689.      Rajendran R, Sunish IP, Mani TR, Munirathinam A, Satyanarayana K. Targeting of children in filariasis mass drug administration. Lancet  2002 Nov 2;360(9343):1430